Lacosamide
- Generic Name
- Lacosamide
- Brand Names
- Motpoly, Vimpat, Lacosamide Adroiq, Lacosamide Accord, Lacosamide UCB
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18N2O3
- CAS Number
- 175481-36-4
- Unique Ingredient Identifier
- 563KS2PQY5
- Background
Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focu...
- Indication
Lacosamide is indicated for the treatment of partial-onset seizures in patients aged one month and older and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients aged four years and older.
- Associated Conditions
- Epilepsy, Primary Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Status Epilepticus
- Associated Therapies
- -
Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2013-08-08
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 192
- Registration Number
- NCT01236001
Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 100
- Registration Number
- NCT01235403
Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 59
- Registration Number
- NCT01190098
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Cognitive and Behavioral Effects of Lacosamide
- First Posted Date
- 2010-08-05
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- Evan Fertig
- Target Recruit Count
- 32
- Registration Number
- NCT01175954
- Locations
- 🇺🇸
Northeast Regional Epilepsy Group, Hackensack, New Jersey, United States
Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT01118949
Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT01118962
- Locations
- 🇺🇸
609, Bethesda, Maryland, United States
🇺🇸601, Nashville, Tennessee, United States
🇺🇸605, Lexington, Kentucky, United States
A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide
- Conditions
- Interventions
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 11
- Registration Number
- NCT01110187
- Locations
- 🇺🇸
UC Health Medical Arts Building, Cincinnati, Ohio, United States
🇺🇸UC Health University Pointe, Cincinnati, Ohio, United States
🇺🇸University Hospital, Cincinnati, Ohio, United States
Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 461
- Registration Number
- NCT00955357
- Locations
- 🇧🇬
703, Blagoevrad, Bulgaria
🇧🇬706, Pleven, Bulgaria
🇧🇬700, Sofia, Bulgaria
An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 366
- Registration Number
- NCT00938912
- Locations
- 🇺🇸
Sp848 016, Pittsburgh, Pennsylvania, United States
🇺🇸Sp848 068, Cincinnati, Ohio, United States
🇺🇸Sp848 061, Las Vegas, Nevada, United States
A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 47
- Registration Number
- NCT00938431
- Locations
- 🇺🇸
012, Tampa, Florida, United States
🇺🇸005, Durham, North Carolina, United States
🇺🇸020, Norfolk, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.